Research programme: monoclonal antibody-based therapeutics - Compugen

Drug Profile

Research programme: monoclonal antibody-based therapeutics - Compugen

Alternative Names: Antibody-based cancer immunotherapies - Compugen; Cancer immunotherapies - Compugen; CGEN 15027-targeted mAb; CGEN 15027-targeted monoclonal antibody; CGEN 15032-targeted immunotherapeutic; CGEN 15052-targeted mAb; CGEN 15052-targeted monoclonal antibody; CGEN 15137-targeted antibody; CGEN 15137/TIGIT; CGEN 671-targeted mAb; CGEN 671-targeted monoclonal antibody; CGEN XXXX; CGEN-15001T-targeted mAb; CGEN-15001T-targeted monoclonal antibody; CGEN-15022-targeted mAb; CGEN-15022-targeted monoclonal antibody; CGEN-15049-targeted mAb; CGEN-15049-targeted monclonal antibody; CGEN-928-targeted mAb; CGEN-928-targeted monoclonal antibody; COM 902; COM902/TIGIT; Immune checkpoint-targeted monoclonal antibodies - Compugen; Splice variant-targeted monoclonal antibody therapeutics - Compugen

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Compugen
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action B7 antigen inhibitors; CD28 antigen inhibitors; Immunomodulators; Membrane protein inhibitors; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Solid tumours
  • Research Malignant melanoma
  • No development reported Haematological malignancies; Multiple myeloma

Most Recent Events

  • 26 Mar 2018 Compugen plans a clinical trial of COM 902 for Cancer in 2019
  • 06 Nov 2017 Compugen enters into a process development and manufacturing service agreement with Bayer HealthCare for COM 902
  • 06 Nov 2017 Compugen announces intention to submit IND for COM 902 to US FDA in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top